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Abstract: The synthesis and pharmacological evaluation of the C-1 
substituted adamantane hydrazones 1a-d, their C-2 substituted 
isomers 2a-d and the C-1 substituted adamantane furanoic 
carboxamides 3a-c is described. The new adamantane derivatives 
exhibited an interesting pharmacological profile, in terms of 
trypanocidal activity and selectivity. Of the compounds tested, the 
phenylacetoxy hydrazone 1b showed the most promising profile 
against African trypanosomes (EC50=11 ± 0.9 nM; SITb=770).  
Vector-borne kinetoplastid diseases, such as Chagas disease 
(CD),[1] leishmaniasis and human African trypanosomiasis (HAT) 
[2] threaten almost a billion people worldwide. [3] The available 
drugs against these neglected tropical diseases (NTDs) are 
characterized by toxicity, limited efficacy and increasing 
resistance.[4] For example, nifurtimox and benznidazole which are 
used against CD, can cause severe side-effects and treatment is 
often unsuccessful. [5] This has led the World Health Organization 
(WHO) to coordinate public sector and private partnerships as part 
of a global effort to develop new and safer dugs. [3] Fexinidazole, 
which was recommended by the European Medicines Agency in 
November 2018, is a successful example of the collaboration 
between the Drugs for Neglected Diseases initiative (DNDi) and 
pharmaceutical chemistry sector. [6] 
 
 
 
 
 
Figure 1. Nifurtimox, benznidazole, fexinidazole and adamantane 
carbohydrazone derivatives. 
 
We have been interested in  adamantane chemistry [7–21] and have 
prepared a large number of analogues in an attempt to exploit 
adamantane’s role in bioactivity. We prepared a series of 
adamantane carbohydrazones,[22] and showed that these 
derivatives are very potent trypanocidals. Following this work, we 
now describe the preparation of a series of phenylhydrazone 
analogues, 1a-d and 2a-d, which in general have very promising 
antitrypanosomal activity. The new derivatives share common 
structural features with nifurtimox and also contain a phenyl 
substituted adamantane ring. The adamantane core of the novel 
adducts accommodates aromatic substitutions at the C-1 and      C-
2 positions. In addition, the 5-nitro-2-furanyl pharmacophore group 
is attached to the phenyladamantane by a hydrazone bond with a 
linker, consisting of one or two methylene groups and an oxygen 
atom. This bond is altered to carboxamide in compounds 3a-c, 
with compound 3c also bearing a benzyl group on the amide 
nitrogen, to mimic the benznidazole skeletal arrangement (Figure 
2). 
 
 
 
 
 
Figure 2. New nifurtimox-adamantane adducts with trypanocidal activity. 
 
The 4-(adamant-1-yl)phenyl)hydrazides, 1a-d, were prepared by 
previously described methods, [22] using as starting materials 
ethyl 4-(adamant-1-yl)benzoate (2), [18] ethyl 4-(adamant-1-
yl)phenyl acetate (4), [18] ethyl 4-(adamant-1-yl)phenylpropionate 
(6) [18] and ethyl 4-(adamant-1-yl)phenoxyacetate (8) [23] as shown 
in Scheme 1. 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: (a) hydrazine hydrate, EtOH, 3 : 160 °C, 
autoclave, 6 d, 81 %, 5 : 130 °C, autoclave, 5 d, 85 %; 7 : reflux, 2 d, 80 %,  9 : 
reflux, 1d, 98 %;(b) 5-nitro-2-furaldehyde, EtOH, r.t., 12 h, 55-80 %.  
 
The preparation of analogues 2a-c was realised by the reaction 
sequence illustrated in Scheme 2. 
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Scheme 2. Reagents and conditions: (a) Jones reagent 8N in acetone, 3 h, 40 %; 
(b) i. SOCl2, gentle reflux, 60 min ii. EtOH (abs.), gentle reflux, 90 min, 79 %; (c) 
hydrazine hydrate, EtOH, 13 : 160 °C, autoclave, 6 d, 55%, 15 : 160 °C, 
autoclave, 6 d, 72%, 18 : reflux, 1 d, 79%; d) 5-nitro-2-furaldehyde, EtOH, r.t.,12 
h, 39-82 %; (e) i. triethyl phosphonoacetate and NaH, anh. THF, 0 °C, Ar, 30 min 
and then at r.t., 60 min ii. saturated ammonium chloride solution, 0 °C, 66 %; (f): 
H2/PtO2, EtOH, 40 psi, r.t., 3 h, 91 %. 
4-(2-Adamantyl)benzaldehyde (10) [17] was oxidised by the Jones 
reagent to the corresponding benzoic acid 11, which was esterified 
to the respective benzoate 12. Under Emmons-Horner reaction 
conditions benzaldehyde 10 afforded the trans-ethyl cinnamate 16, 
which was then hydrogenated to the corresponding saturated 
propionate 17. Ethyl 4-(adamant-2-yl)benzoate (12), ethyl 4-
(adamant-2-yl)phenylacetate (14) [17] and  ethyl 4-(adamant-2-
yl)phenylpropionate (17) gave the desired hydrazones 2a-c via 
standard procedures.  
 
 The synthesis of the 2-(4-(adamant-2-yl)phenoxy)-N'-((5-
nitrofuran-2-yl)methylene)acetohydrazide (2d) is shown in 
Scheme 3. 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: (a) ClCH2CO2Et, K2CO3, dry DMF, 83 %; 
(b) hydrazine hydrate, EtOH, reflux, 1 d, 98 %; (c) 5-nitro-2-furaldehyde, EtOH, 
r.t.,12 h, 92 %. 
 
The 4-(2-adamantyl)phenol (19), [24,25] was  ethoxycarbonylome- 
thylated in the presence of potassium carbonate in dry DMF to 
afford the respective phenoxyacetate 20, which led to the 
corresponding hydrazone 2d following the above methods. Due to 
the inefficiency of the literature methods for the preparations of     
4-(2-adamantyl)phenol (19), we developed the alternative 
synthetic routes to 19, shown in Scheme 4. 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Reagents and conditions: (a) i. 4-methoxyphenylmagnesium 
bromide, Et2O/THF, Ar, r.t., 3 h, ii. HCl 10%, 0 °C, 75 %; (b) i. TFA, DCM, Ar, r.t., 
15 min, ii. Et3SiH, Ar, r.t., 1 h, iii. H2O, 0 °C, 24:72 %, 27:56 %; (c) i. BBr3, DCM, 
r.t., ii. H2O, 0 °C, 97 %; (d) n-BuLi, THF, -80 oC; e) i. adamantanone, -80 oC ii. 
H2O, 0 °C, 45 %; (f) H2/10% Pd-C, EtOAc, 2 h, almost quant. yield. 
The first route involves the reaction of 4-methoxyphenyl- 
magnesium bromide with 2-adamantanone (22) to give the 
carbinol 23, which was then reduced to the                                                
2-(4-methoxyphenyl)adamantane (24). O-demethylation of 24 led 
to the desired phenol 19 in 52% overall yield (from adamantanone 
22). The second reaction pathway involved the lithiation of the aryl 
bromide 25, [26] which  was added to the 2-adamantanone (22) to 
give the 2-(4-(benzyloxy)phenyl)adamantan-2-ol (26). This was 
sequentially reduced and hydrogenated to give                                       
4-(2-adamantyl)phenol (19) in 25 % overall yield (from the aryl 
bromide 30). 
 
The N-substituted-5-nitrofuran-2-carboxamides 3a-c were 
prepared as shown in Scheme 5. 
 
 
Scheme 5. Reagents and conditions: (a) i. SOCl2, reflux, 1 h, ii. benzylamine, 
THF, r.t., 2 h, 83 %; (b) i. LiAlH4, THF, reflux, 2 h ii. EtOH, H2O, NaOH 10%, 0 °C, 
83 %; (c) i. 5-nitro-2-furoic acid, SOCl2, reflux, 1 h, ii. appropriate amine 28, 29, 
32, acetone/pyridine, dropwise, r.t., 1 d, 43-53 %.  
 
4-(1-Adamantyl)benzoic acid (30) [18] was converted to the                
4-(adamant-1-yl)-N-benzylbenzamide (31), which was then 
reduced to the respective benzylamine 32. The methanamine 28, 
[27] the ethanamine 29 [27] and the benzylamine 32 were coupled 
with the intermediate, 5-nitro-2-furoic chloride, to afford the desired 
amides 3a-c, as shown in Scheme 5.  
 
The new nifurtimox-adamantane adducts were tested for their 
activity against the bloodstream form Trypanosoma brucei and 
Trypanosoma cruzi epimastigotes and the results are shown in 
Tables 1 and 2.  
 
Table 1. Anti-T. brucei screening of nifurtimox-adamantane derivatives. 
 [a] EC50 and EC90; concentration that inhibits growth by 50% and 90%, 
respectively. [b] S.I.; selectivity index, the ratio of EC50 values obtained with L6 
cells and T. brucei. 
 
Table 2. Anti-T. cruzi screening of nifurtimox-adamantane derivatives. 
 [a] EC50 and EC90; concentration that inhibits growth by 50% and 90%, 
respectively. [b] S.I.; selectivity index, the ratio of EC50 values obtained with L6 
cells and T. cruzi. 
 
It is apparent that the hydrazone nifurtimox-adamantane adducts 
1a-d and 2a-d are more potent trypanocidals than the parent drug 
Cmpd 
T. brucei 
EC50 (nM)[a] 
T. brucei 
EC90 (nM)[a] 
L6 cells 
EC50 (μM)[a] 
S.I. 
EC50 L6/Tb[b] 
Ia 19.0 ± 1.00 28.0 ± 4.00 1.85 ± 0.08 95 
Ib 11.0 ± 0.90 23.9 ± 0.60 8.49 ± 0.17 770 
Ic 15.9 ± 1.80 36.9 ± 12.4 8.28 ± 0.24 520 
Id 29.0 ± 1.00 35.0 ± 1.00 3.04 ± 0.21 105 
2a 41.0 ± 3.00 81.0 ± 18.0 - - 
2b 12.4 ± 0.40 25.2 ± 1.90 2.90 ± 0.40 235 
2c 17.4 ± 1.80 41.2 ± 5.90 3.74 ± 0.36 215 
2d 87.0± 5.00 172 ± 9.00 - - 
a 881 ± 66.0 1230 ± 20.0 14.5 ± 0.40 16 
3b 353 ± 38.0 488 ± 10.0 4.06 ± 0.23 12 
3c 322 ±17.0 653 ± 51.0 1.38 ± 0.15 4.3 
Nifurtimox    2510 ± 90 [28]    
Cmpd 
T. cruzi 
EC50 (nM)[a] 
T. cruzi 
EC90 (nM)[a] 
L6 cells 
EC50 (μM)[a] 
S.I. 
EC50 L6/Tc [b] 
Ia 178 ± 13.0 404 ± 81.0 - - 
Ib 33.9 ± 2.00 63.0 ± 5.00 8.49 ± 0.17 250 
Ic 70.7 ± 13.8 193 ± 7.00 8.28 ± 0.24 115 
Id 85.0 ± 9.00 196 ± 7.00 - - 
2a 170 ± 5.00 330 ± 5.00 - - 
2b 55.4 ± 1.20 112 ± 3.00 2.90 ± 0.40 52 
2c 95.2 ± 19.0 245 ± 14.0 3.74 ± 0.36 39 
2d 330 ± 4.00 873 ± 9.00 - - 
3a 16200 ± 500 26600 ± 200 14.5 ± 0.40 0.9 
3b 770 ± 89.0 1880 ± 43.0 4.06 ± 0.23 5.3 
3c 1550 ± 140 5340 ± 190 1.38 ± 0.15 0.9 
Nifurtimox    3100 ± 500[29]    
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(I) and 3 – 9 fold more effective against T. brucei than T. cruzi. The 
most active adduct, with the best selectivity, was the 
phenylacetoxy hydrazone 1b (EC50=11±0.9 nM and SITb=770). 
The spacer between the phenyl ring and the carbonyl group seems 
to have a significant impact on activity and cytotoxicity. It seems 
that the present structural modification comprising of a phenyl ring 
insertion between the adamantane core and the hydrazone side 
chain has improved the pharmacological characteristics of the new 
molecules, in terms of activity and toxicity, compared to the  
adamantane carbohydrazones (IV), we previously reported.[22] The 
direct attachment of the hydrazone linker to the phenyl ring 
decreased the potency, and a one or two methylene spacer was 
associated with enhanced activity. Adducts 1b, 1c and 2b, 2c 
exhibited higher trypanocidal activity than analogues 1a and 2a, 
respectively. Conversely, the replacement of one methylene by an 
oxygen atom had a detrimental impact on activity. The position of 
substitution on the adamantane core (C-1, C-2), influenced 
cytotoxicity and the C-1 substituted hydrazones 1b (SITb=770) and 
1c (SITb=520) were found to be more selective than the 
corresponding C-2 substituted adducts 2b (SITb=235) and 2c 
(SITb=215). The same pattern was also observed in the T. cruzi 
results. The third series of derivatives, the 5-nitro-furonic 
carboxamides 3a-c, exhibited reduced activity in comparison to 
the hydrazones, which implies that these analogues may follow the 
same mechanistic pathway as nifurtimox. [30–32] This observation is 
in agreement with our previous test results on adamantane 
carbohydrazones (IV). [22] 
In conclusion, the new nifurtimox-adamantane hydrazone adducts 
show higher trypanocidal potency than both the parent drug (I) and 
the adamantane carbohydrazones (IV). The optimum potency 
arose from the combination of 4-(adamant-1-yl)phenyl substitution 
and a two methylene spacer, whilst their 4-(adamant-2-yl)phenyl 
substituted isomers were almost equipotent but less selective.  
Experimental Section 
General procedure for the preparation of hydrazones 1a-d and 2a-d. 
A solution of the respective hydrazide (0.96 mmol) in ethanol (5 mL) was 
added to a solution of 5-nitro-2-furaldehyde (200 mg, 1.42 mmol) in ethanol 
(5 mL). The mixture was stirred under Argon in darkness for 12 h. The 
resulting precipitate was filtered, washed with a small amount of ethanol 
and dried to give the corresponding product as a yellow solid, which was 
recrystallized from chloroform. 
 
General procedure for the preparation of carboxamides 3a-c. 
 5-Nitro-2-furoic acid (240 mg, 1.52 mmol) was treated with SOCl2 (10 mL) 
at 60-65 oC for 60 min. Excess SOCl2 was removed under reduced 
pressure and subsequently by azeotropic distillation with benzene (5 mL). 
The residue obtained was dissolved in anhydrous acetone (10-15 mL) and 
a solution of the respective amine (1.44 mmol) in anhydrous pyridine (2 mL) 
was added dropwise under stirring. The reaction mixture was stirred at 
room temperature for 1 d, the solvent removed in vacuo and the residue 
was treated with water. The resulting mixture was extracted with CH2Cl2 
and the organic extracts washed with water, 10% sol. HCl and water. The 
combined organic phases were dried over Na2SO4 and the solvent 
evaporated. The crude product was purified by gradient flash column 
chromatography, using as eluent a mixture of CH2Cl2/MeOH, to give the 
corresponding carboxamide as an orange viscous semi-solid, which was 
recrystallized from chloroform. 
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The insertion of a phenyl ring between the adamantane core and the hydrazone side chain of the new nifurtimox-adamantane adducts 
led to a higher trypanocidal activity and lower toxicity than the parent drug. The most active adduct with the best selectivity is the 
phenylacetoxy hydrazone 1b (EC50=11 ± 0.9 nM and SITb=770). 
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